CN104491567A - 一种治疗不安腿综合征的中药及其制备方法 - Google Patents
一种治疗不安腿综合征的中药及其制备方法 Download PDFInfo
- Publication number
- CN104491567A CN104491567A CN201410689506.8A CN201410689506A CN104491567A CN 104491567 A CN104491567 A CN 104491567A CN 201410689506 A CN201410689506 A CN 201410689506A CN 104491567 A CN104491567 A CN 104491567A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- rhizoma
- caulis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 208000005793 Restless legs syndrome Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000009636 Huang Qi Substances 0.000 claims abstract description 20
- 241000283956 Manis Species 0.000 claims abstract description 20
- 241000237636 Pheretima Species 0.000 claims abstract description 20
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 210000000582 semen Anatomy 0.000 claims abstract description 20
- 241000522620 Scorpio Species 0.000 claims abstract description 13
- 239000009490 scorpio Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 239000012567 medical material Substances 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- -1 dry Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 241000239226 Scorpiones Species 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000002435 tendon Anatomy 0.000 abstract description 2
- 241000722953 Akebia Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000013465 muscle pain Diseases 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 2
- 229960000911 benserazide Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XUDUTRMKKYUAKI-UHFFFAOYSA-N 3-[1-(1-phenylethyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2C(NC3=CC=CC=C32)=O)CCN1C(C)C1=CC=CC=C1 XUDUTRMKKYUAKI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,具体涉及一种治疗不安腿综合征的中药及其制备方法。该中药由以下重量份的中药原料药制成:玉竹25-35份,黄芪15-25份,当归10-20份,桂枝15-25份,白芍10-20份,甘草6-14份,续断15-25份,鸡血藤25-35份,木通4-8份,地龙10-20份,桑寄生10-20份,薏苡仁25-35份,白术20-30份、夜交藤15-25份,羌活6-14份、穿山甲3-7份,全蝎3-7份。该药物具有补气养血通络,祛风除湿,柔筋止痛的功效。临床用于治疗不安腿综合征,总有效率高达94.17%,治愈率可达到79.17%。
Description
技术领域
本发明属于医药技术领域,具体涉及一种治疗不安腿综合征的中药及其制备方法。
背景技术
不安腿综合征临床上多见于中老年人群,特别是女性多于男性,常常表现在夜晚睡觉时两条腿,小腿部更加明显,表现出症状多种多样。但是有共同的特点是说疼而又不是疼,说麻木痒的感觉而不是麻木痒,病人表现出说不清的很多症状。伸腿、腿均不能缓解其不舒服的症状,表现懊恼无可奈何,甚者整个夜晚不能睡眠。白天关节、肌肉等又没有任何阳性体征。
不安腿综合征的病因还不十分清楚,与劳累、情绪、下肢循环、神经化学递质的释放、缺乏某些微量元素、年龄老化退化等可能有关系。化学药多用多巴胺能类药物来治疗,但是,多巴胺能类药物的毒副作用较大,常规量不能改善控制症状的话,是不能再加大剂量的。其它还有提出用镇静、催眠和抗惊厥药物来治疗,甚至有包括吗啡类制剂,因这些西药制剂都存在共同的缺点,如成瘾性和依赖性停药后的反弹性、剂量逐渐加大等不良反应。
因此,需要寻找用于治疗不安腿综合征的疗效好,不良反应少的药物。
发明内容
本发明所要解决的技术问题是避免上述现有技术所存在的不足之处,提供一种治疗不安腿综合征的中药,该药物具有补气养血通络,祛风除湿,柔筋止痛的功效。用于治疗不安腿综合征,具有治愈率和有效率高,不良反应少的优点。
本发明所要解决的另一技术问题是提供该中药的剂型及其制备方法。
本发明是通过如下技术方案实现的:
一种治疗不安腿综合征的中药,由以下重量份的中药原料药制成:
玉竹25-35份,黄芪15-25份,当归10-20份,桂枝15-25份,白芍10-20份,甘草6-14份,续断15-25份,鸡血藤25-35份,木通4-8份,地龙10-20份,桑寄生10-20份,薏苡仁25-35份,白术20-30份、夜交藤15-25份,羌活6-14份、穿山甲3-7份,全蝎3-7份。
优选的,上述的治疗不安腿综合征的中药,由以下重量份的中药原料药制成:
玉竹28-32份,黄芪18-22份,当归13-17份,桂枝18-22份,白芍13-17份,甘草8-12份,续断18-22份,鸡血藤28-32份,木通5-7份,地龙13-17份,桑寄生13-17份,薏苡仁28-32份,白术23-27份、夜交藤18-22份,羌活8-12份、穿山甲4-6份,全蝎4-6份。
更优选的,上述的治疗不安腿综合征的中药,由以下重量份的中药原料药制成:
玉竹30份,黄芪20份,当归15份,桂枝20份,白芍15份,甘草10份,续断20份,鸡血藤30份,木通6份,地龙15份,桑寄生l5份,薏苡仁30份,白术25份、夜交藤20份,羌活10份、穿山甲5份,全蝎5份。
上述的治疗不安腿综合征的中药,该中药组合物的剂型形式为口服制剂,优选为颗粒剂。
上述的治疗不安腿综合征的中药的制备方法,包含如下步骤:
(a)将地龙、穿山甲、全蝎粉碎成细粉备用;
(b)将玉竹、黄芪、白芍、甘草、续断、鸡血藤、木通、桑寄生、薏苡仁、白术、夜交藤11味药材加上述药材8~12倍重量的水煎煮2次,每次煎煮1-2小时,合并两次的煎出液,于60℃下减压浓缩至原煎出液体积的一半,倾出放凉,滤过,滤液60℃减压浓缩至相对密度为1.25~1.28的清膏;
(b)将当归、桂枝、羌活用药材体积3-5倍量的75%乙醇浸泡12小时后回流提取2次,每次1-2小时,过滤,合并滤液,滤液在0.05~0.07MPa下减压回收乙醇至药液无醇味儿,60℃减压浓缩至相对密度为1.14~1.18的清膏;
(d)合并两部分清膏及步骤(a)所得的细粉,混匀,减压干燥,粉碎,过100目筛,加入药学上可接受的辅料,混匀,以75%乙醇作润湿剂制粒,干燥,整粒,即得。
优选的,上述的治疗不安腿综合征的中药的制备方法中,所述步骤(1)中加水量为药材10倍重量,每次煎煮1.5小时。
优选的,上述的治疗不安腿综合征的中药的制备方法中,所述步骤(2)中加75%乙醇量为药材4倍体积,每次回流提取1.5小时。
上述的治疗不安腿综合征的中药的制备方法,详细步骤如下:
(a)将地龙、穿山甲、全蝎粉碎成细粉备用;
(b)将玉竹、黄芪、白芍、甘草、续断、鸡血藤、木通、桑寄生、薏苡仁、白术、夜交藤11味药材加上述药材10倍重量的水煎煮2次,每次煎煮1.5小时,合并两次的煎出液,于60℃下减压浓缩至原煎出液体积的一半,倾出放凉,滤过,滤液60℃减压浓缩至相对密度为1.25~1.28的清膏;
(b)将当归、桂枝、羌活用药材体积4倍量的75%乙醇浸泡12小时后回流提取2次,每次1.5小时,过滤,合并滤液,滤液在0.05~0.07MPa下减压回收乙醇至药液无醇味儿,60℃减压浓缩至相对密度为1.14~1.18的清膏;
(d)合并两部分清膏及步骤(a)所得的细粉,混匀,减压干燥,粉碎,过100目筛,加入药学上可接受的辅料,混匀,以75%乙醇作润湿剂制粒,干燥,整粒,即得。
所述的药学上可接受的辅料选自:蔗糖、淀粉、硬脂酸镁、甘露醇、山梨醇、山梨酸或钾盐、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素A、维生素C、维主素E、维生素D、氮酮、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、丙二醇、乙醇、吐温60~80、司班~80、蜂蜡、羊毛脂、液体石蜡、十六醇、没食子酸酯类、琼、三乙醇胺、碱性氨基酸、尿素、尿囊素、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β~环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙等。
本发明的治疗不安腿综合征的中药具有补气养血通络,祛风除湿,柔筋止痛的功效,临床用于治疗不安腿综合征。
玉竹一般用于养阴生津,《本经》谓玉竹“主中风暴热,不能动握,跌筋伤肉,诸不足”,证之临床,该药用于积劳伤筋、气血凝滞的风痛诸疾,有柔筋通络、祛风止痛之良效,故以此为主药;黄芪、当归益气养血;白芍、甘草和营柔筋止痛;配木通舒筋通络;鸡血藤、续断、桑寄生、地龙养血通络,祛风除湿,柔筋止痛;薏苡仁、白术健脾燥湿,脾胃强则湿气自除;桂枝、羌活辛温散寒,温经通络,宣痹止痛;夜交藤调和阴阳,对于夜间加重不安腿综合症有特效;穿山甲、全蝎活血祛风通络。诸药合用,使气血充足,经得所养,风寒湿邪消除,而诸症可愈。
具体实施方式
下面结合具体实施例对本发明作更进一步的说明,以便本领域的技术人员更了解本发明,但并不因此限制本发明。
实施例1:本发明中药组合物颗粒剂的制备
处方:玉竹300g,黄芪200g,当归150g,桂枝220g,白芍150g,甘草100g,续断200g,鸡血藤300g,木通60g,地龙150g,桑寄生l50g,薏苡仁300g,白术250g、夜交藤400g,羌活100g、穿山甲50g,全蝎50g。
制备方法:
(a)将地龙、穿山甲、全蝎粉碎成细粉备用;
(b)将玉竹、黄芪、白芍、甘草、续断、鸡血藤、木通、桑寄生、薏苡仁、白术、夜交藤11味药材加上述药材10倍重量的水煎煮2次,每次煎煮1.5小时,合并两次的煎出液,于60℃下减压浓缩至原煎出液体积的一半,倾出放凉,滤过,滤液60℃减压浓缩至相对密度为1.25~1.28的清膏;
(b)将当归、桂枝、羌活用药材体积4倍量的75%乙醇浸泡12小时后回流提取2次,每次1.5小时,过滤,合并滤液,滤液在0.05~0.07MPa下减压回收乙醇至药液无醇味儿,60℃减压浓缩至相对密度为1.14~1.18的清膏;
(d)合并两部分清膏及步骤(a)所得的细粉,混匀,减压干燥,粉碎,过100目筛,加入蔗糖,混匀,以75%乙醇作润湿剂制粒,干燥,整粒,即得。
共制备1000g,产品进行质量检验,检验合格后包装消毒。每袋重10g,每日服三次,每次1袋。
实施例2:本发明中药组合物颗粒剂的制备
处方:玉竹280g,黄芪220g,当归130g,桂枝220g,白芍130g,甘草120g,续断180g,鸡血藤320g,木通50g,地龙170g,桑寄生130g,薏苡仁320g,白术230g、夜交藤220g,羌活80g、穿山甲60g,全蝎40g。
制备方法:
(a)将地龙、穿山甲、全蝎粉碎成细粉备用;
(b)将玉竹、黄芪、白芍、甘草、续断、鸡血藤、木通、桑寄生、薏苡仁、白术、夜交藤11味药材加上述药材8倍重量的水煎煮2次,每次煎煮1小时,合并两次的煎出液,于60℃下减压浓缩至原煎出液体积的一半,倾出放凉,滤过,滤液60℃减压浓缩至相对密度为1.25~1.28的清膏;
(b)将当归、桂枝、羌活用药材体积3倍量的75%乙醇浸泡12小时后回流提取2次,每次1小时,过滤,合并滤液,滤液在0.05~0.07MPa下减压回收乙醇至药液无醇味儿,60℃减压浓缩至相对密度为1.14~1.18的清膏;
(d)合并两部分清膏及步骤(a)所得的细粉,混匀,减压干燥,粉碎,过100目筛,加入蔗糖,混匀,以75%乙醇作润湿剂制粒,干燥,整粒,即得。
共制备1000g,产品进行质量检验,检验合格后包装消毒。每袋重10g,每日服三次,每次1袋。
实施例3:本发明中药组合物颗粒剂的制备
处方:玉竹320g,黄芪180g,当归170g,桂枝180g,白芍170g,甘草80g,续断220g,鸡血藤280g,木通70g,地龙130g,桑寄生170g,薏苡仁280g,白术270g、夜交藤180g,羌活120g、穿山甲40g,全蝎60g。
制备方法:
(a)将地龙、穿山甲、全蝎粉碎成细粉备用;
(b)将玉竹、黄芪、白芍、甘草、续断、鸡血藤、木通、桑寄生、薏苡仁、白术、夜交藤11味药材加上述药材12倍重量的水煎煮2次,每次煎煮2小时,合并两次的煎出液,于60℃下减压浓缩至原煎出液体积的一半,倾出放凉,滤过,滤液60℃减压浓缩至相对密度为1.25~1.28的清膏;
(b)将当归、桂枝、羌活用药材体积5倍量的75%乙醇浸泡12小时后回流提取2次,每次2小时,过滤,合并滤液,滤液在0.05~0.07MPa下减压回收乙醇至药液无醇味儿,60℃减压浓缩至相对密度为1.14~1.18的清膏;
(d)合并两部分清膏及步骤(a)所得的细粉,混匀,减压干燥,粉碎,过100目筛,加入蔗糖,混匀,以75%乙醇作润湿剂制粒,干燥,整粒,即得。
共制备1000g,产品进行质量检验,检验合格后包装消毒。每袋重10g,每日服三次,每次1袋。
实施例4:本发明中药组合物颗粒剂的制备
处方:玉竹250g,黄芪250g,当归100g,桂枝250g,白芍100g,甘草140g,续断150g,鸡血藤350g,木通40g,地龙200g,桑寄生100g,薏苡仁350g,白术200g、夜交藤250g,羌活60g、穿山甲70g,全蝎30g。
制备方法同实施例1。
共制备1000g,产品进行质量检验,检验合格后包装消毒。每袋重10g,每日服三次,每次1袋。
实施例5:本发明中药组合物颗粒剂的制备
处方:玉竹350g,黄芪150g,当归200g,桂枝150g,白芍200g,甘草60g,续断250g,鸡血藤250g,木通80g,地龙100g,桑寄生200g,薏苡仁2550g,白术300g、夜交藤150g,羌活140g、穿山甲30g,全蝎70g。
制备方法同实施例1。
共制备1000g,产品进行质量检验,检验合格后包装消毒。每袋重10g,每日服三次,每次1袋。
对本发明实施例1制备的颗粒剂进行了临床试验,详情如下:
1临床资料
200例患者均经过系统地观察、诊断排除其它器质性病变。用其它方法和药物治疗效果不佳,愿意合作,我们作了细致的记录、随访、观察,本组180例,分本发明中药组(治疗组)120例,多巴胺能类药物(对照组)80例。其中男性84例,女性116例;年龄45-60岁90例,61-70岁80例,80岁以上4例;平均病程6年,本病四季均可发生,冬春季节为甚。
2治疗方法
治疗组给予本发明实施例制备的治疗不安腿综合征的中药颗粒剂,每次1袋,每日三次,饭后服用。服药期间忌食辛辣。
对照组给予多巴胺能类药物多巴丝肼片(62.5mg,每晚1次,按常规给药)。
7天为1疗程,并评定疗效,7天后观察评价结果,让患者自述治疗结果是痊愈、显效或无效。
3 疗效标准
7天内不安腿综合征消失,并随访3个月未再复发的为痊愈;
显效为7天内有明显的效果,症状减轻,而且是不影响睡觉,随访时3个月内有复发出现,但经服药后又能使症状消失的;
无效为7天后患者自述无症状改善者。
4 治疗结果
结果见表1。
表1 两组治疗结果比较
组别 | n | 痊愈(例) | 显效(例) | 无效(例) | 痊愈率(%) | 总有效率(%) |
治疗组 | 120 | 95 | 18 | 7 | 79.17** | 94.17** |
对照组 | 80 | 26 | 35 | 19 | 32.50 | 76.25 |
注:与对照组比较,**P<0.01
结果为7天内不安腿综合征症状消失的,治疗组95例(79.17%),对照组26例(32.50%);显效:治疗组18例(15.00%),对照组35例(43.75%);无效:治疗组为7例(5.83%),对照组19例(23.75%)。治愈率治疗组为79.17%,对照组32.50%;总有效率治疗组为94.17%,对照组为76.25%,两组差异性非常显著,(P<0.01),表明治疗组优于对照组。
4.不良反应
两组不良反应比较 常见的不良反为口干、头晕、便秘和食欲减退。对照组有2例患者因不能耐受多巴丝肼片的头晕症状而退出治疗,见表2。
表2 两组不良反应发生率比较(例,%)
组别 | n | 口干 | 头晕 | 便秘 | 食欲减退 | 嗜睡 |
治疗组 | 120 | 0(0%) | 1(0.83%) | 0(0%) | 0(0%) | 0(0%) |
对照组 | 80 | 15(18.75%**) | 8(10.00%**) | 6(7.5%**) | 12(15.00%**) | 14(17.50%**) |
注:与对照组比较,**P<0.01。
Claims (9)
1.一种治疗不安腿综合征的中药,由以下重量份的中药原料药制成:
玉竹25-35份,黄芪15-25份,当归10-20份,桂枝15-25份,白芍10-20份,甘草6-14份,续断15-25份,鸡血藤25-35份,木通4-8份,地龙10-20份,桑寄生10-20份,薏苡仁25-35份,白术20-30份、夜交藤15-25份,羌活6-14份、穿山甲3-7份,全蝎3-7份。
2.根据权利要求1所述的治疗不安腿综合征的中药,其特征在于,由以下重量份的中药原料药制成:
玉竹28-32份,黄芪18-22份,当归13-17份,桂枝18-22份,白芍13-17份,甘草8-12份,续断18-22份,鸡血藤28-32份,木通5-7份,地龙13-17份,桑寄生13-17份,薏苡仁28-32份,白术23-27份、夜交藤18-22份,羌活8-12份、穿山甲4-6份,全蝎4-6份。
3.根据权利要求2所述的治疗不安腿综合征的中药,其特征在于,由以下重量份的中药原料药制成:
玉竹30份,黄芪20份,当归15份,桂枝20份,白芍15份,甘草10份,续断20份,鸡血藤30份,木通6份,地龙15份,桑寄生l5份,薏苡仁30份,白术25份、夜交藤20份,羌活10份、穿山甲5份,全蝎5份。
4.根据权利要求1或2或3所述的治疗不安腿综合征的中药,其特征在于,该中药组合物的剂型形式为口服制剂。
5.根据权利要求4所述的治疗不安腿综合征的中药,其特征在于,该中药组合物的剂型形式为颗粒剂。
6.权利要求1或2或3所述的治疗不安腿综合征的中药的制备方法,包含如下步骤:
(a)将地龙、穿山甲、全蝎粉碎成细粉备用;
(b)将玉竹、黄芪、白芍、甘草、续断、鸡血藤、木通、桑寄生、薏苡仁、白术、夜交藤
11味药材加上述药材8~12倍重量的水煎煮2次,每次煎煮1-2小时,合并两次的煎出液,于60℃下减压浓缩至原煎出液体积的一半,倾出放凉,滤过,滤液60℃减压浓缩至相对密度为1.25~1.28的清膏;
(b)将当归、桂枝、羌活用药材体积3-5倍量的75%乙醇浸泡12小时后回流提取2次,每次1-2小时,过滤,合并滤液,滤液在0.05~0.07MPa下减压回收乙醇至药液无醇味儿,60℃减压浓缩至相对密度为1.14~1.18的清膏;
(d)合并两部分清膏及步骤(a)所得的细粉,混匀,减压干燥,粉碎,过100目筛,加入药学上可接受的辅料,混匀,以75%乙醇作润湿剂制粒,干燥,整粒,即得。
7.根据权利要求5所述的治疗不安腿综合征的中药的制备方法,其特征在于,所述步骤(1)中加水量为药材10倍重量,每次煎煮1.5小时。
8.根据权利要求5所述的治疗不安腿综合征的中药的制备方法,其特征在于,所述步骤(2)中加75%乙醇量为药材4倍体积,每次回流提取1.5小时。
9.根据权利要求5所述的治疗不安腿综合征的中药的制备方法,详细步骤如下:
(a)将地龙、穿山甲、全蝎粉碎成细粉备用;
(b)将玉竹、黄芪、白芍、甘草、续断、鸡血藤、木通、桑寄生、薏苡仁、白术、夜交藤
11味药材加上述药材10倍重量的水煎煮2次,每次煎煮1.5小时,合并两次的煎出液,于60℃下减压浓缩至原煎出液体积的一半,倾出放凉,滤过,滤液60℃减压浓缩至相对密度为1.25~1.28的清膏;
(b)将当归、桂枝、羌活用药材体积4倍量的75%乙醇浸泡12小时后回流提取2次,每次1.5小时,过滤,合并滤液,滤液在0.05~0.07MPa下减压回收乙醇至药液无醇味儿,60℃减压浓缩至相对密度为1.14~1.18的清膏;
(d)合并两部分清膏及步骤(a)所得的细粉,混匀,减压干燥,粉碎,过100目筛,加入药学上可接受的辅料,混匀,以75%乙醇作润湿剂制粒,干燥,整粒,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410689506.8A CN104491567A (zh) | 2014-11-26 | 2014-11-26 | 一种治疗不安腿综合征的中药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410689506.8A CN104491567A (zh) | 2014-11-26 | 2014-11-26 | 一种治疗不安腿综合征的中药及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104491567A true CN104491567A (zh) | 2015-04-08 |
Family
ID=52933081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410689506.8A Pending CN104491567A (zh) | 2014-11-26 | 2014-11-26 | 一种治疗不安腿综合征的中药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104491567A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106389829A (zh) * | 2016-06-14 | 2017-02-15 | 高超 | 一种治疗骶髂关节致密性骨炎的中药及其制备方法 |
CN108837139A (zh) * | 2018-09-30 | 2018-11-20 | 宋双敬 | 一种治疗不安腿综合征的中药组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1317315A (zh) * | 2000-04-11 | 2001-10-17 | 潘秋兰 | 安筋止痛制剂 |
CN103463586A (zh) * | 2013-08-22 | 2013-12-25 | 英山县人民医院 | 一种治疗不安腿综合征的中药组合物 |
-
2014
- 2014-11-26 CN CN201410689506.8A patent/CN104491567A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1317315A (zh) * | 2000-04-11 | 2001-10-17 | 潘秋兰 | 安筋止痛制剂 |
CN103463586A (zh) * | 2013-08-22 | 2013-12-25 | 英山县人民医院 | 一种治疗不安腿综合征的中药组合物 |
Non-Patent Citations (1)
Title |
---|
郎立和: "益气活血舒筋汤治疗不安腿综合征25例", 《河南中医》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106389829A (zh) * | 2016-06-14 | 2017-02-15 | 高超 | 一种治疗骶髂关节致密性骨炎的中药及其制备方法 |
CN108837139A (zh) * | 2018-09-30 | 2018-11-20 | 宋双敬 | 一种治疗不安腿综合征的中药组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102342992B (zh) | 一种用于治疗失眠的中药组合物及其制剂的制备方法 | |
CN102068682A (zh) | 一种治疗消化系统疾病的中药组合物及其制备方法 | |
CN103990081A (zh) | 一种中药组合物及其在制备治疗婴幼儿黄疸药物中的用途 | |
CN101954006B (zh) | 治疗失眠的中药 | |
CN101926882A (zh) | 治疗癌症的药物组合物及其制备方法 | |
CN103638451A (zh) | 一种治疗慢性肝炎的中药及其制备方法 | |
CN103432559A (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN104491567A (zh) | 一种治疗不安腿综合征的中药及其制备方法 | |
CN103330837B (zh) | 一种治疗绝经妇女骨质疏松症的中药组合物 | |
CN103055111B (zh) | 一种治疗小儿疳积的中药组合物及其制备方法 | |
CN102430097A (zh) | 一种治疗白癜风的中药 | |
CN108671165A (zh) | 一种治疗女性更年期综合征的中药汤剂 | |
CN102552520A (zh) | 一种治疗胸痹心痛的活血止痛药物及制备工艺和应用 | |
CN105521332A (zh) | 治疗肛裂的中药组合物及其制备方法和应用 | |
CN105169279A (zh) | 一种治疗膝关节骨质增生的中药组合物 | |
CN101721653A (zh) | 一种治疗甲状腺机能亢进的中药 | |
CN104173584A (zh) | 治疗风湿的中药 | |
CN108904617A (zh) | 治疗脑血管疾病的药物组合物及其制备方法和用途 | |
CN102671032B (zh) | 一种治疗复发性口疮的中药 | |
CN104189615B (zh) | 一种治疗崩漏的中药制剂及其制备方法 | |
CN103845690A (zh) | 一种治疗老年抑郁症的药物 | |
CN103656199B (zh) | 一种治疗肾阴不足证型咳嗽的中药 | |
CN102793874B (zh) | 降低狼疮肾炎患者血尿和蛋白尿的中药制剂 | |
CN102406913A (zh) | 一种治疗郁证的中药组合物 | |
CN105770815A (zh) | 一种含有艾叶的治疗产后虚脱的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150408 |